Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Elly Marcq 1 , Jorrit De Waele 1 , Jonas Van Audenaerde 1 , Eva Lion 2 , Eva Santermans 3 , Niel Hens 3, 4 , Patrick Pauwels 1, 5 , Jan P. van Meerbeeck 1, 6, * and Evelien L.J. Smits 1, 2, * 1 Center for Oncological Research, University of Antwerp, Antwerp, Belgium 2 Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium 3 Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium 4 Center for Health Economics Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium 5 Department of Pathology, Antwerp University Hospital, Antwerp, Belgium 6 Thoracic Oncology/MOCA, Antwerp University Hospital, Antwerp, Belgium * Shared senior authors Correspondence to: Elly Marcq, email: Elly.Marcq@uantwerpen.be Keywords: mesothelioma, immune checkpoints, effusions, tumor microenvironment, flow cytometry Received: April 21, 2017 Accepted: September 01, 2017 Published: September 21, 2017 ABSTRACT Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify prognostic and/or predictive biomarkers and provide useful insights for developing effective immunotherapy. In this context, we investigated the immune cell composition of effusions (pleural and ascites fluids) from 11 different chemotherapy-treated MPM patients. We used multicolor flow cytometry to describe different subsets of immune cells and their expression of immune checkpoint molecules TIM-3, LAG-3, PD-1 and PD-L1. We demonstrate a patient-dependent inter- and intraspecific variation comparing pleural and ascites fluids in immune cell composition and immune checkpoint expression. We found CD4 + and CD8 + T cells, B cells, macrophages, natural killer cells, dendritic cells and tumor cells in the fluids. To the best of our knowledge, we are the first to report TIM-3 and LAG-3 expression and we confirm PD-1 and PD-L1 expression on different MPM effusion-resident immune cells. Moreover, we identified two MPM effusion-related factors with clinical value: CD4+ T cells were significantly correlated with better response to chemotherapy, while the percentage of PD-L1 + podoplanin (PDPN) + tumor cells is a significant prognostic factor for worse outcome. Our data provide a basis for more elaborate research on MPM effusion material in the context of treatment follow-up and prognostic biomarkers and the development of immune checkpoint-targeted immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
Chéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84
Cited by
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
“Malignant pleural mesothelioma TILs High PD-1/PD-L1 expression, and immune cell activation [45]”
BackgroundThe Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
“There is no expression of LAG-3 on mesothelial cells themselves (67), but high levels of LAG-3 can be detected in pleural effusions of patients with mesothelioma (68,69), and tumor infiltrating lymphocytes (TILs) in pleural effusions from patients with mesothelioma express high levels of this receptor (70).”
BackgroundMesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
“Pleural effusions of MPM patients have shown a strong infiltration of activated cytotoxic and helper T cells; however, most of them are associated with T cell exhaustion markers, such as PD-1+, TIM-3, LAG-3, that negatively regulate lymphocyte activity [72].”
Background
Metadata
- Authors
- Marcq, E., Waele, J. D., Audenaerde, J. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-09-21
- Volume
- 8
- Issue
- 52
- Pages
- 89722-89735
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2758966180
- Cited by
- 57
- References
- 5
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. https://app.cochat.ai/papers/10.18632/oncotarget.21113
- The paper
- Marcq, E., Waele, J. D., Audenaerde, J. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J. (2017). Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget. https://doi.org/10.18632/oncotarget.21113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.